DE Yung et al. Inflamm Bowel Dis 2018; 24: 2327-38. This systematic review and meta-analysis of four studies “did not detect an increased risk of postoperative complications with preoperative vedolizumab” (VDZ). This study included 281 patients who received VDZ.
SC Ng et al. Inflamm Bowel Dis 2018; 24: 2431-41. The authors examined the frequency of opportunistic infection among 4 VDZ trials and postmarketing surveillance, accounting for ~114,000 patient-years of exposure. The most common infection was C difficile (0.5 per 100 patient-years); tuberculosis was reported at 0.1 per 100 patient years. This study showed “that the rate of serious opportunistic infections in patients receiving VDZ was low and most patients could continue VDZ treatment.”
SL Gold et al. Gastroenterol 2018; 155: 981-2. This clinical image showed a case of Henoch-Schonlein Purpura (HSP) that developed in a 53 year receiving VDZ.
E Shmidt et al. Inflamm Bowel Dis 2018; 24: 2461-7. This retrospective review of a prospectively maintained IBD registry provides information of risk factors for VDZ loss of response and management. 444 patients out of 788 who received VDZ had a significant response.The majority of VDZ recipients 75) had failed prior anti-TNF Rx. Key points:
- Loss of response (LOR) at 6 months and 12 months was 20% and 35% respectively
- UC patients compared to Crohn’s disease (CD) patients were more likely to have LOR with R of 1.54.
- Shortening VDZ infusion interval from q8 weeks to q4-6 weeks recaptured response in 49% and led to remission in 18% of this cohort.
- LOR was more common (2-fold) among those who had a LOR to anti-TNF agent. Patients with primary nonresponse were less likely to have LOR with VDZ.
U Kopylov et al. Inflamm Bowel Dis 2018; 24: 2442-51. This retrospective multicenter study examined VDZ effectiveness among anti-TNF naive patients, n=184.
- For CD, 42/50 (82%) responded by week 14, and 32 (64%) were in clnical remission. At last followup (30-52 weeks), clinical remission was noted in 24/35 (69%)
- For UC, 116/134 (79%) responded at week 14 and 53 (40%) were in clinical remission. At last followup (30-52 weeks), 67% were in remission (69/103)
The authors conclude that VDZ is similarly efffective for anti-TNF naive CD and UC patients.
My take: These studies show that we still have a lot to learn about the effectiveness of VDZ as its use becomes more widespread.
Related blog posts:
- Vedolizumab and Extraintestinal Manifestations
- VICTORY consortium showing good results for vedolizumab
- Summary of latest information on Vedolizumab
- GI Care for Kids Data on Vedolizumab 2017
- Latest on Vedolizumab
- Pediatric Experience with Vedolizumab | gutsandgrowth
- Vedolizumab -another new IBD treatment | gutsandgrowth